FRANKLIN LAKES, N.J., March 14, 2012 /PRNewswire/ -- The final results of the Additional KIF6 Risk Offers Better Adherence to Statins (AKROBATS) study will be presented at the American College of Cardiology's 61st Annual Scientific Session & Expo being held March 24-27, 2012, in Chicago, IL. The AKROBATS study is a collaborative effort between the Medco Research Institute, a subsidiary of Medco Health Solutions, Inc. (NYSE: MHS) and Quest Diagnostics (NYSE: DGX), the world's leading diagnostic testing company.
(Logo: http://photos.prnewswire.com/prnh/20100609/MEDCOLOGO )
Session Number: 1258
Session Type: ACC Moderated Poster Contributions
Session Start/End Time: Monday, Mar 26, 2012, 9:30 AM -10:30 AM
Location: McCormick Place South, Hall A
Presentation Number: 1258-376
Abstract Title: Patient knowledge of pharmacogenetic information improves adherence to statin therapy: Results of the Additional KIF6 Risk Offers Better Adherence to Statins (AKROBATS) trial.
Presenter: Scott L. Charland, Pharm.D., Medco Research Institute
AKROBATS is prospective, nonrandomized intervention trial of the effect of KIF6 testing results reported directly to the patient on statin adherence and persistence over six months. All eligible intervention and control patients were greater than or equal to 18 years old, new to statin therapy (none 6 months prior), and from the same sponsored plans (which had granted permission for their members to participate in the study). Genetic testing for a common single nucleotide polymorphism (rs20455) resulting in an arginine to tryptophan substitution at position 719 (Trp719Arg) in the kinesin-like protein 6 gene (KIF6) was conducted and written results returned to the patient within 30 days of initiating statin therapy, and before the first statin prescription refill. Tested patients were matched to concurrent, non-tested control patients on age, gender, statin prescription distribution channel, and the number of chronic medications at time of statin initiation. The primary endpoint was statin adherence (proportion of days covered; PDC) at six months. Secondary end points included achievement of adherence (PDC greater than or equal to 0.80) and persistence to statin therapy at six months. AKROBATS is registered on www.clinicaltrials.gov (NCT01068834).
About Medco Research Institute
Medco Research Institute® is an evidence-based research organization focused solely on novel research, analytics and new discoveries that close the gap between scientific discovery and medical practice for improved patient outcomes and lower overall healthcare costs. More information about the Medco Research Institute's peer-reviewed research can be found at www.medcoresearch.com.
Medco Health Solutions, Inc. (NYSE: MHS) is pioneering The world's most advanced pharmacy® and its clinical research and innovations are part of Medco making medicine smarter for millions of Americans.
With more than 20,000 employees worldwide dedicated to improving patient health and reducing costs for a wide range of public and private sector clients, and 2011 revenue of $70 billion, Medco ranks 34th on the 2011 Fortune 500 list and is named among the world's most innovative, most admired and most trustworthy companies.
For more information, go to http://www.medcohealth.com.
About Quest Diagnostics and Berkeley HeartLab
Quest Diagnostics, the world's leading diagnostic testing company, offers genetic and non-genetic testing through Berkeley HeartLab, the company's business unit specializing in advanced cardiovascular disease testing. Berkeley HeartLab offers the 4myheart program, an educational program for patients that provides personalized care, including for medication adherence, to help patients improve their cardiac health. Quest Diagnostics offers a laboratory-developed test for the KIF6 gene variant through Berkeley HeartLab. For more information, visit www.QuestDiagnostics.com or www.4myheart.com.
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the risks and uncertainties that affect our business, particularly those mentioned in the Risk Factors section of the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission.
SOURCE Medco Health Solutions, Inc.